Podcasts about Pancreatic cancer

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Pancreatic Cancer⁠⁠ ⁠⁠from the Oncology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Featuring perspectives from Dr Eileen M O'Reilly and Dr Philip A Philip, including the following topics: Introduction (0:00) Optimal Incorporation of Chemotherapy into the Management of Advanced Pancreatic Cancer — Dr Philip (7:27) Other Available and Emerging Novel Approaches for Pancreatic Cancer — Dr O'Reilly (28:05) CME information and select publications

We're dropping this bonus episode because something genuinely historic happened in oncology and we couldn't wait until our regular schedule to talk about it. Dr. Mark Lewis, GI medical oncologist, pancreatic cancer survivor, and one of our absolute favorite guests. He just got back from ASCO, the Super Bowl of oncology, where a new drug called daraxonrasib received one of only about six standing ovations in the conference's history, including applause that broke out mid-sentence when researchers showed the survival data on-screen. The drug targets a mutation that drives the vast majority of pancreatic cancer and has been considered "undruggable" for decades and it works not by attacking the mutation directly, but by cutting off the downstream signals it sends, like snipping the wire instead of fighting with the switch. The results are remarkable. In patients who had already received standard chemotherapy, daraxonrasib roughly doubled survival time and delivered it in pill form rather than an IV every two weeks, a meaningful quality-of-life difference for people who are already facing the hardest year of their lives. Mark walks us through the science, the side effects (rash, because RAS proteins live in skin too), the path to FDA approval, and what this means beyond pancreatic cancer, the same KRAS mutations show up in about 30% of lung cancers and 40% of colon cancers. Takeaways: Pancreatic cancer has been devastatingly hard to treat, 85% of patients are incurable at diagnosis because it spreads silently and there's no good screening, leaving most patients with a median survival of about a year on IV chemotherapy. KRAS, the mutation driving nearly all pancreatic cancer, was long considered "undruggable", the protein was so smooth and spherical that no drug could bind to it, and researchers were actively discouraged from pursuing it as a target. Daraxonrasib works by cutting the power rather than fighting the switch, instead of binding to the KRAS protein itself, it uses molecular glue to interrupt the downstream growth signals the mutation sends, an approach that took decades to develop and wasn't taken seriously until now. The trial results roughly doubled survival and the treatment is a daily pill, not an IV, patients who had already been treated with chemotherapy gained approximately an additional year of life with improved quality of life, which represents one of the most significant advances in pancreatic cancer treatment in decades. This breakthrough has implications far beyond the pancreas, KRAS mutations drive about 30% of lung cancers and 40% of colon cancers too, and proving the target is druggable opens the door to a new generation of treatments across multiple cancer types. Want more Dr. Mark Lewis? X: @marklewismd To Get Tickets to Wife & Death: You can visit Glaucomflecken.com/live  We want to hear YOUR stories (and medical puns)! Shoot us an email and say hi! knockknockhi@human-content.com Can't get enough of us? Shucks. You can support the show on Patreon for early episode access, exclusive bonus shows, livestream hangouts, and much more! –⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ http://www.patreon.com/glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Also, be sure to check out the newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://glaucomflecken.com/glauc-to-me/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you are interested in buying a book from one of our guests, check them all out here: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.amazon.com/shop/dr.glaucomflecken⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ If you want more information on models I use: Anatomy Warehouse provides for the best, crafting custom anatomical products, medical simulation kits and presentation models that create a lasting educational impact.  For more information go to Anatomy Warehouse DOT com. Link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://anatomywarehouse.com/?aff=14⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Plus for 15% off use code: Glaucomflecken15 -- A friendly reminder from the G's and Tarsus: If you want to learn more about Demodex Blepharitis, making an appointment with your eye doctor for an eyelid exam can help you know for sure. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.EyelidCheck.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for more information.  Produced by⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Human Content⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

What are some of your more expensive habits? What impact does summer have on your spending? In this week's episode of the podcast, Shawn & George talk about summer's most expensive habits, including: Weddings / Vacations / Family Outings Summer Camps & Kids Activities Concerts Home Improvement Projects Pets Subscriptions Back to School Shopping Cost of Living Changes What other summer spending habits do you have? Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team (until June 30, 2026) at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.   We discussed: The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients. The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib. The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors. Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice. The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment! #PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

Your body is a buffet. Don’t let cancer put you out of business!

BUFFALO, NY – June 8, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on June 3, 2026, titled “The anticancer effects of PCAIs in pancreatic cancer cells involve MAPK and PI3K/AKT pathways hyperactivation.” The study was led by first author Kweku Ofosu-Asante and corresponding author Nazarius S. Lamango from the Florida A&M University College of Pharmacy and Pharmaceutical Sciences, Institute of Public Health in Tallahassee, Florida. Pancreatic ductal adenocarcinoma is among the deadliest forms of cancer, due in large part to the high frequency of KRAS mutations that drive tumor growth and resistance to treatment. Although targeted therapies have recently been developed for specific KRAS mutations, many patients continue to have limited treatment options, highlighting the need for broader strategies capable of targeting multiple KRAS-driven cancers. In this study, researchers investigated a class of experimental compounds known as polyisoprenylated cysteinyl amide inhibitors (PCAIs), which were originally designed to disrupt abnormal KRAS signaling. Using pancreatic cancer cell lines carrying KRAS mutations, the team explored how these compounds affect cancer cell survival, migration, invasion, and the molecular pathways that regulate tumor growth. Full press release - https://www.oncotarget.com/news/pr/experimental-compounds-trigger-cancer-cell-death-in-kras-driven-pancreatic-cancer/ DOI - https://doi.org/10.18632/oncotarget.28879 Correspondence to - Nazarius S. Lamango - nazarius.lamango@famu.edu Abstract video - https://www.youtube.com/watch?v=asbhjME7rFQ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28879 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCAIs, PDAC, MAPK, PI3K/AKT, KRAS To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

#thismorning | #Molecule to #Medicine: How Daraxonrasib is #Rewriting Pancreatic #Cancer #Drug #Development | Andrew R. Snyder, PhD., Monash University | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #wellness

Luke O'Neil, professor of biochemistry in the school of biochemistry and immunology at Trinity College Dublin Joined Pat as always on a Saturday, but this time from Sarajevo. This week Luke spoke to Pat about a major conference happening in Chicago, where the world's leading cancer specialists and researchers are coming together to share how they are working to fight the disease.

Pancreatic Cancer Halted by Virus Injection Researchers injected an engineered virus directly into pancreatic tumors in three patients — the virus replicated inside malignant cells, triggered an immune response, and stopped tumor growth and spread at an intentionally low early dose. Host Dave Asprey breaks down why oncolytic viruses can do what chemotherapy can't, how the tumor's dense biological wall becomes less of an advantage when a virus can replicate inside it directly, and why a measurable response at a safety dose is the kind of early signal that changes how he's watching this field. Sources: https://www.newscientist.com AI Chatbots and Teen Mental Health A new survey shows roughly one in five adolescents and young adults are now going to AI chatbots when they feel sad, anxious, nervous, or stressed, with usage heaviest in the 18–21 range. Host Dave Asprey explains why general-purpose language models designed to be engaging are dangerous as a substitute for real mental health support, why false reassurance from a chatbot may make the pipeline to real care harder to reach, and why this is a health systems story masquerading as a tech adoption story — and what parents need to do about it. Sources: https://www.nbcnews.com GLP-1 Drugs Cut Breast Cancer Risk Penn Medicine published a retrospective analysis of over 111,000 women finding GLP-1 exposure associated with about 35% lower odds of breast cancer in the full cohort and around 30% lower in a matched comparison group. Host Dave Asprey breaks down why this isn't just a weight loss story — it's a metabolic dysfunction story — explains the insulin resistance, inflammation, and hormonal environment mechanisms that may be driving the signal, and makes the case that this finding should be reshaping how oncologists and OBGYNs think about high-risk patients right now. Sources: https://www.pennmedicine.org Putin's $26 Billion Longevity Program The Wall Street Journal reports that Russia has made anti-aging research a Kremlin-level national priority through a $26 billion program including gene therapy, organ bioprinting, and xenotransplantation, led by Putin's daughter Maria Vorontsova and physicist Mikhail Kovalchuk. Host Dave Asprey breaks down what's geopolitical theater, what's legitimately frontier science, and why the real question is whether any findings will make it out to the broader research community or get locked inside a state program. Sources: https://www.wsj.com https://www.france24.com Sauna vs. Cold Plunge A landmark Finnish study tracked over 2,300 men for nearly 21 years and found increasing sauna frequency associated with dramatically lower cardiovascular and all-cause mortality — strongest at four or more sessions per week. Host Dave Asprey settles the debate with the actual data, explains what heat shock proteins and cold shock proteins actually are and why the evidence base behind them is nowhere near equivalent, and calls out the wellness marketing presenting early-stage mouse model research as the cold water equivalent of two decades of human mortality outcomes. Sources: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2521522 This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on cancer treatment breakthroughs, adolescent mental health and AI, metabolic drivers of disease, geopolitical longevity science, and the real evidence behind popular recovery modalities. Host Dave Asprey connects emerging clinical research, objective epidemiological data, and real-world optimization protocols into actionable frameworks for extending healthspan, sharpening performance, and staying ahead of the science. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: oncolytic virus pancreatic cancer, engineered virus tumor treatment, AI chatbot teen mental health, adolescent AI emotional support, GLP-1 breast cancer risk, semaglutide cancer prevention, metabolic dysfunction root cause disease, Putin longevity program Russia, New Health Preservation Technologies, anti-aging biotech geopolitics, sauna longevity mortality data, cold plunge cold shock proteins, RBM3 heat shock proteins, sauna vs cold plunge evidence, biohacking news 2026, longevity research, Dave Asprey, The Human Upgrade Thank you to our sponsors! - Suppgrade Labs | Grab your DAKE and Minerals 101 duo at shopsuppgradelabs.com and use code DAVEPOD for 15% off today - Essentia | Go to https://myessentia.com/dave and use code DAVE for $100 off The Dave Asprey Upgrade. - iRestore | Reverse hair loss at www.irestore.com/DAVE and get exclusive savings on the iRestore Elite, use code DAVE Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 00:00 – Intro 00:42 – Pancreatic Cancer Halted by Virus Injection 01:44 – Teens & AI Therapy Chatbots 03:13 – GLP-1 Drugs Cut Breast Cancer Risk 04:30 – Russia's $26B Longevity Program 06:18 – Sauna vs. Cold Plunge 09:10 – Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Send Zorba a message!Zorba explains a breakthrough treatment for advanced pancreatic cancer that nearly doubles the survival rate.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

Send Zorba a message!Zorba explains a breakthrough treatment for advanced pancreatic cancer that nearly doubles the survival rate.Support the showProduction, edit, and music by Karl ChristensonSend your question to Dr. Zorba (he loves to help!):Phone: 608-492-9292 (call anytime)Email: askdoctorzorba@gmail.comWeb: www.doctorzorba.orgStay well!

It is officially  the start of Hurricane Season in Florida! Are you prepared? What are some funny hurricane truths? How much water should you have?  Toilet paper? Flash lights and batteries? How should you prepare your family and your business for the financial impact of a storm? On this week's episode of The Crushing Debt Podcast, Shawn & George talk about these topics, including whether you are financially ready personally and professionally for a storm, what you need to know or do to protect your family and your business, all with our unique Crushing Debt spin! Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026. The link will be open through the end of June!

SMH's Kolschowsky Research and Education Institute is enrolling patients in a research study evaluating LINFU (Low-Intensity Non-Focused Ultrasound), an emerging screening technology designed to help doctors identify precancerous changes in people at high risk for pancreatic cancer, but who have no signs or symptoms of the disease. Kenneth Meredith, MD, chief of gastrointestinal oncology at SMH's Brian D. Jellison Cancer Institute and principal investigator of the local study, says the screening represents an important step forward in pancreatic cancer research. You can also watch the video recording on our Vimeo channel here. For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Headlines: – Welcome to Mo News + Taylor Swift ‘Toy Story' Single (02:00) – Florida Sues OpenAI and Sam Altman Over AI Risks For Kids (04:30) – Claude Maker Anthropic Files For IPO, Setting Up Public-Market Test Of AI Boom (08:20) – US Bombs Iranian Military Sites,Then Downs Missiles Tehran Fired At Troops In Kuwait (12:00) – Iran Warns Israeli Attacks In Lebanon Threaten Ceasefire With US; Trump Says “Shooting Will Stop” (18:00) – Why The Trump Administration Plans To Drop Its "Weaponization" Fund (20:45) – Pancreatic Cancer 'Miracle' Drug Daraxonrasib Doubles Survival Rate In New Trial (25:00) – Scott Pelley Accuses CBS News Boss of ‘Murdering' ‘60 Minutes' (28:30) – Judge Rules Charlie Kirk Suspect's Hearing Will Be Open To The Public (38:00) – Serena Williams Returns to Pro Tennis After Four-Year Hiatus (40:10) – On This Day In History (45:00) Thanks To Our Sponsors: – Monarch - 50% off your first year | Code: MONEWS – Factor - 50% off your first box | Code: monews50off –⁠ Industrious⁠ - Coworking office. 50% off day pass | Code: MONEWS50 – LMNT | Free Sample Pack with any LMNT drink mix or 12oz cans purchase

Oncologist Austin Duffy discusses the development of a new daily drug for panceatic cancer.

June 2, 2026 ~ Dr. Philip Philip, World Renowned Oncologist with Henry Ford Health discusses the new drug that could be a game changer in fighting pancreatic cancer. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

⚡ Myoscience Electrolyte Sticks with Creatine — 20% off exclusively for Ben's audience : https://bit.ly/4efbmfS 

A medical breakthrough in the fight against pancreatic cancer is showing promising results after decades of research. The experimental drug, taken once a day, extends patients' lives by slowing the progression of one of the deadliest cancers. Dr. Rachna Shroff, associate director of clinical investigations at the University of Arizona Comprehensive Cancer Center, joins Stephanie Sy for more. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

The CEO of Kalshi joins to discuss the company's latest product announcements and the regulatory environment for prediction markets. Then, Former Defense Secretary Mark Esper helps break down the latest headlines on the war with Iran. We also speak with the CEO of D-Wave Quantum following the U.S. government's recent investment in quantum companies. Plus, the CEO of Revolution Medicines joins to discuss the company's pancreatic cancer drug that nearly doubled survival rates.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively. Topics Covered: Overview of the RASolute-302 study Impact of Daraxonrasib on overall survival RAS mutations in pancreatic cancer Mechanism of action of RAS inhibitors Side effects and management strategies Tune in now for an enlightening discussion on the future of pancreatic cancer treatment! #ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival

CBC News has a draft copy of the federal government's long-delayed strategy on artificial intelligence. It's promising to create up to 90,000 jobs, protect Canadians against the risks of AI, and massively boost the number of businesses that use it.And: A new drug for pancreatic cancer is showing unprecedented promise. In a trial, it doubled survival time for patients who had already gone through one round of chemotherapy. It's not on the market yet, but it is a sign of progress in treating one of the deadliest forms of cancer.Also: It's one of the fastest growing games in Canada. But the organization in charge of cricket in this country is under increasing fire. The sport's international governing body has suspended its membership after an investigation by CBC's The Fifth Estate put a spotlight on issues of corruption and allegations of match fixing.Plus: Prime Minister Carney outlines plan to deal with antisemitism, U.S.-Iran negotiations, and more.

Medical researchers are hailing a new drug to treat the world's most deadly cancer as the biggest breakthrough in decades. Auckland University's Associate Professor of Oncology, Dr Ben Lawrence spoke to John Campbell.

AP correspondent Donna Warder reports on a pill that's helping some patients with advanced pancreatic cancer live longer.

This week, we take a "back to the future" look at the early-stage pancreatic cancer phase, a relatively stagnant area in terms of pivotal trials. The two trials are the ESPAC4 trial, which examines doublet chemotherapy in pancreatic cancer, and Josh does a traditional deep dive into the world of neoadjuvant chemotherapy. He highlights ESPAC-5, PREOPANC-2, and the TAPS consortium, to name a few. A complicated but overall evolving field.Studies discussed in this episode:ESPAC-4FOLFOXIRIPREOPANC-2ESPAC-5TAPS (Trans-Atlantic Pancreatic Surgery (TAPS) Consortium Study)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Mike Fitzpatrick was diagnosed with pancreatic cancer in 1999.  That he is still with us in and of itself is amazing; what is even more incredible is that he later learned he had been walking around with symptoms of the disease since 1986!  When he initially reported the symptoms to doctors, they performed some tests and claimed at worst he had a twisted bowel.  Mike went to a different doctor who ran an MRI and a CT scan and told Mike he had pancreatic cancer.   After discussing the diagnosis with his wife, they decided to be proactive and opted for a Whipple Procedure, a complex, 13-hour procedure that got rid of hundreds of tiny tumors on his pancreas.  However, in 2018, more tumors were back.  They were removed with a nanoknife procedure, but Mike was told for the rest of his life he would have to take lanreotide, a monthly injection to keep the tumors at bay.   His health seemed to be just fine until 1986, when Mike experienced pain shooting through his abdomen and back.  He found himself with severe diarrhea and sustained vomiting for twenty minutes at a time.  Mike sought medical attention.  Despite doctors running various tests, they said there was nothing wrong with him that indicated cancer, and that the worst possible scenario was twisted bowel.   In 1999, Mike went to another doctor who performed a CT scan and an MRI.  Shortly thereafter, he and his wife were called to the doctor's office where they were told Mike had pancreatic cancer.  The doctor urged Mike to undergo a Whipple Procedure to get rid of hundreds of small tumors on his pancreas.  When he asked the doctor of the consequences should Mike pass on the Whipple Procedure, Mike was told the consequences could be sudden death because the tumors could "explode."  Mike and his wife chose to go ahead with the Whipple Procedure.   It was a 13-hour surgery.  Mike had his gall bladder, bile duct and part of his pancreas removed.  Then the bile duct was re-attached to his small intestine so that he could eat and digest food.  Mike said his recovery from the procedure took close to one year, but the tumors were gone.   All seemed well for Mike until 2018 when two tumors were detected.  This time he underwent a nanoknife procedure.  He was told the tumors were gone, but in 2024, they reappeared.  His doctor told him that for the rest of his life, Mike would have to get a monthly injection of lanreotide, aimed at keeping the tumors from spreading.   Mike Fitzpatrick is glad to be alive, but suffers from neuropathy, which results in chronic fatigue and a loss of balance.    Additional Resources:   The Pancreatic Cancer Action Network: https://www.pancan.org   The Cancer Support Studio: https://www.cancersupportstudio.com   The One Cancer Place Institute: https://www.onecancerplace.org   Mike's Blog: 50 for Fitz, available on Facebook, LinkedIn and Instagram              

Why do people think bankruptcy is bad? True, it has a negative stigma and it will be a hit to your credit score, but why is bankruptcy perceived as a massive negative? Is bankruptcy the best solution for everyone?  Put simply, no it is not, but it is better than most people will admit. On this week's episode of The Crushing Debt Podccast, Shawn and George talk about rising debt levels, rising gas prices, rising grocery prices ... prices increasing everywhere, and what that means for someone considering bankruptcy. Plus what are some of the negatives of waiting too long to file?  What is the difference between bankruptcy and negotiating the debt? What is the impact of the automatic stay?  And what is life like after bankruptcy? Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com. And there is still time, until June 30, 2026 to donate to Pancreatic Cancer research and education by joining Shawn's 2026 PanCAN team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026

Pancreatic cancer is a devastating diagnosis, and the statistics are alarming. According to the latest research, it's the third leading cause of cancer-related deaths in the US, with over 50,000 people losing their lives each year. The disease is particularly aggressive, with a survival rate of just six to seven months after diagnosis. In this episode, our guest, Dr. Greg Verdine, shares his insights on a promising new treatment that could reshape the way we approach pancreatic cancer. Dr. Verdine, a professor of chemistry at Harvard and CEO of LifeMine Therapeutics, discusses the challenges of treating pancreatic cancer, including its tendency to be asymptomatic until late stages and its resistance to chemotherapy. He explains how a new daily pill, currently in early trial stages, targets the cancer's genetic mutations and has shown promising results in extending patients' lifespans. The conversation delves into the complexities of pancreatic cancer, including its unique characteristics that make it difficult to treat. Dr. Verdine highlights the importance of this new treatment, which has the potential to double patients' lifespans and pave the way for further research. If you're interested in learning more about this breakthrough treatment and the future of pancreatic cancer research, tune in to this episode to hear Dr. Verdine's expert insights and the potential for a brighter outlook on this devastating disease.See omnystudio.com/listener for privacy information.

A Huntington Beach, California, high school senior honors her dying father by holding an early graduation for herself, fulfilling both their wishes. AND Tragedy hit my own Tennessee community on March 27, 2026, when a middle school bus on a field trip got into an accident. To see videos and photos referenced in this episode, visit GodUpdates! https://www.godtube.com/blog/high-school-senior-honors-dying-father.html https://www.godtube.com/blog/church-helping-community-after-bus-crash.html Discover more Christian podcasts at lifeaudio.com and inquire about advertising opportunities at lifeaudio.com/contact-us.

What if “energy healing” could be tested—and measured—in a world-class cancer research setting?In this episode of Unpacking Possibility, host Traci Stein unpacks a groundbreaking MD Anderson Cancer Center preclinical study investigating biofield therapy (energy healing) and its reported effects on pancreatic cancer in lab and animal models—including slower growth and spread.Traci shares the findings of this study and discusses them in the broader context of research on biofield therapies (including Reiki, Healing Touch, and Therapeutic Touch). She also shares a personal story about doing Reiki in an operating room for a patient who was undergoing heart surgery and how what she witnessed deepened her perspective on subtle energy. You'll also learn a simple, at-home exercise you can try to begin sensing your own energy field (as well as a friend's).In this episode you'll learn more about:- What the MD Anderson studies found- Why pancreatic cancer research needs new possibilities - Early research showing energy healing could make seeds germinate faster, surgical wounds heal better, and more- A brief look at the Bengston Healing Method and “image cycling” - A simple exercise you can try tonight to explore energy-field sensing Note: This episode is educational and not medical advice. Always consult your healthcare team about diagnosis and treatment.To learn more about Traci's self-paced, online course, “Developing Everyday Intuition,” visit: https://www.drtracistein.com/developing-everyday-intuition-courseTo receive $5 off the price of Traci's course, “Developing Everyday Intuition,” apply code ENERGY5OFF before checkout.“The Everything Guide to Integrative Pain Management,” by Traci Stein, PhD, MPH: https://a.co/d/0fji41kQTo read the MD Anderson paper: https://onlinelibrary.wiley.com/doi/10.1002/cam4.71726

Join us as we review recent articles and news featured in The DIGEST, including updated lipid guidelines, GLP1 agonists holds and procedures, the newest drug in pancreatic cancer, and discontinuing thyroid supplementation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Nora Taranto (@norataranto), Laura Glick (@lauraglick) and Matt Watto (@doctorwatto).Claim free CME for this episode at curbsiders.vcuhealth.org!Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME!Credits Written and Hosted by: Nora Taranto MD MSCE, Laura Glick MD,  Matthew Watto MD, FACP Cover Art:  Nora Taranto MD MSCE Reviewers: Emi Okamoto MD  Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro and pun   Lipid Management Guidelines Overview  Emerging Treatments in Oncology  Press Release on a new KRAS Inhibitor for Pancreatic Cancer  Perioperative Considerations for GLP-1 Use  Deprescribing Levothyroxine in Older Adults Sponsor: Panacea FinancialIf you're about to make the leap into  residency and feeling the financial pressure of that transition, visit  PanaceaFinancial.com/curbsiders today. Sponsor: UpToDatefor a limited time, get 10% off UpToDate packages with code CURB10. Visit store.uptodate.com to save on your annual or longer personal UpToDate subscription today. 

The pandemic triggered something unexpected:  American fathers started working less and spending significantly more time on childcare and housework — and new research suggests it wasn't remote work or job loss driving the shift, but a genuine realignment of gender norms. Plus: some scientists are calling this the biggest advancement in cancer treatment in 15 years – a drug called daraxonrasib which is nearing FDA approval and substantially extends the lives of pancreatic cancer patients; Brazil has officially begun demarcating over a million acres of protected land for an uncontacted Indigenous tribe in the Amazon; and Oklahoma became the 17th U.S. state to ban child marriage, ruffling some feathers.  What Could Go Right? is produced by The Progress Network and Kaleidoscope. For transcripts, to join the newsletter, and for more information, visit: theprogressnetwork.org Subscribe to our (FREE) Substack newsletter: https://theprogressnetwork.org/newsletter/ Watch the podcast on YouTube: / theprogressnetwork Follow us on X, Instagram, Facebook, TikTok: @progressntwrk Follow Emma on Instagram: https://www.instagram.com/heyemmavarv/

Today, we accidentally skipped early pancreatic cancer and jumped straight to advanced pancreatic cancer. It was a sombre episode, with clinicians and advocates screaming for better treatment options for this cancer. While small incremental advances have been made, the holy grail remains elusive.Today our focus is on NAPOLI-3, the use of liposomal irinotecan (NALIRIFOX), and PANOVA-3, where TTFields are used in combination with gemcitabine/abraxane. A good conversation, though the current premise is sad. Hopefully, as time moves on, this conversation will be more optimistic. Studies discussed in this episode:NAPOLI-3PANOVA-3For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Broadcast from KSQD, Santa Cruz on 5-21-2026: This is the second show featuring Mira Achilles, a UCSC graduate working on her masters in epidemiology. Dr. Dawn and Mira open with a Harvard study showing OpenAI's o1 reasoning model reached correct diagnoses 67% of the time versus 50-55% for physicians, and scored 89% versus 34% on treatment plans. The AI advantage shrinks when doctors get more data and time, suggesting its greatest value is in fast-moving triage. Dr. Dawn cautions that over-reliance on AI during residency could undermine the clinical reasoning neurologic pathways doctors must develop, and emphasizes the "zebra paradox"— rare diseases remain rare even when symptoms match the textbook. Dr. Dawn shares a personal case of a patient with throat shingles, leading her to use a medical AI (OpenEvidence) to investigate Shingrix risks. An Australian study found an elevenfold increase in shingles within 21 days of the first Shingrix dose in adults over 65, though dose two reduced overall risk by 73%. She explains this could be one of several things such as immune reconstitution inflammatory syndrome (IRIS), or that the AS01B vaccine adjuvant's strong activation may transiently reactivate latent virus, and recommends valacyclovir prophylaxis for high-risk patients for their first Shringrex shot.. Mira discusses AI in education, noting the shift from professors threatening plagiarism charges to teaching students how to critique AI output, emphasizing taking summaries "with a grain of salt." Dr. Dawn describes Chinese research scanning 1,154 children that identified a third ADHD subtype—severe emotional dysregulation—showing 45 abnormal brain regions versus 26 in the inattentive and hyperactive-impulsive types, with standard stimulants working poorly for this group. She connects this to traditional psychiatric personality disorder classifications and A discussion of vagus nerve stimulation's emerging applications for autoimmune conditions. Dr. Dawn and Mira discuss menstruation and bodily autonomy, then describe the Somedays period pain simulator that uses electrical impulses to let men experience menstrual cramps, highlighting differing pain thresholds. An emailer references a Radiolab episode about deliberate hookworm infection to treat asthma and allergies. Dr. Dawn explains parasites release immunosuppressants to survive, including anti-inflammatory protein-2 (AIP) now in drug development, which stimulates T-regulatory cells and IL-10 while "alarmins" inhibit lung inflammation—though this increases vulnerability to new infections. A caller with H. pylori and frequent viral infections asks whether S. boulardii and reuteri probiotics are safe given her low immunity. Dr. Dawn explains immunosuppression warnings target transplant-level drug suppression, not a tendency toward viruses like hers. Dr. Dawn thinks that her near-zero natural killer cells explain frequent infections, and suggests that the H. pylori test given her absence of symptoms, may be an incidental bystander rather than the cause of her low ferritin, which suggests bleeding. In medical news of the weird, Dr. Dawn describes Baby Cassian, diagnosed in utero with congenital high airway obstruction syndrome (CHAOS), who was partially removed from the womb at 25 weeks for airway surgery, returned, and born again at 31 weeks—leading to a discussion of microsurgery and how specialties partition by the physical scale of the surgery rather the location or type of structure.

FDA Commissioner Marty Makary officially resigned last week following reports of his ouster. Then, the acting directors for the agency's two main review units also left their posts, as did the FDA chief of staff and chief AI officer. Domino effect aside, the reaction from the industry has been mostly positive, given Makary's tumultuous reign. But he might be hard to replace. If it were up to the biotech industry, former longtime oncology regulator and short-lived CDER director Richard Pazdur would take the role. For now, FDA Deputy Commissioner for Food Kyle Diamantas is in charge.Eli Lilly's David Ricks was the highest paid pharma CEO last year, but J&J's Joaquín Duato made the most relative to rank-and-file employees, with a median pay ratio of 358 to one. He was on the top of BioSpace's list last year, too, with a ratio of 293 to 1. Last month, Revolution Medicines' RAS inhibitor doubled survival in a Phase 3 pancreatic cancer trial. This week, Truist Securities went so far as to nominate RevMed as “the next oncology titan,” a title currently held by Merck and its blockbuster cancer drug Keytruda. Safety continues to challenge the gene therapy space, especially in Duchenne muscular dystrophy. Late last week, REGENXBIO announced mixed results from a Phase 3 program—the gene therapy did lead to functional improvements, but two serious adverse events caused the stock to drop 37%.Finally, Amgen's rare disease drug Tavneos continues to face scrutiny. Last month, the FDA alleged that doctored data were filed to support Tavneos' initial approval. Now, it's been linked to 20 deaths in Japan.

This episode of the PeerDirect Medical News Podcast explores promising new data on the oral pan-RAS inhibitor daraxonrasib in KRAS-mutated pancreatic cancer, a randomized stroke trial evaluating adjunctive tirofiban after tenecteplase, and AI-driven breast cancer risk prediction models that may outperform breast density alone. Together, these studies highlight emerging advances in targeted oncology, acute stroke management, and precision screening technologies that could influence future clinical practice.

Brian shares inspiring patient stories—melanoma, pancreatic, lymphoma—showing how raw food and mindset helped reverse terminal diagnoses. #CancerRecovery #LifestyleMedicine #HealthTalks

How is that summer body, bathing suit body coming along? Every year around this time… people start talking about getting their summer body ready; eating better… hitting the gym… cutting back… but nobody's talking about their summer budget. Just like your body, if you ignore it all year and panic in May, things get uncomfortable real fast! Summer bodies vs. summer budgets! On this week's episode of the Crushing Debt Podcast, Shawn & George talk about how to get back on track with your finances as we approach summer, including Things that prevent you from getting your finances under control, like "I'll start Monday," "I'll start next paycheck," gym membership, budget apps you don't open, cheat meals, "It's just one swipe," no plan, no tracking, quick fixes, or balance transfers & "later" thinking; Where summer wrecks your budget, like vacations, kids out of school (extra spending), events, weddings, parties, travel + eating out, or "It's summer, I deserve it" mindset. We talk about a simple 30-Day Reset to get your money back on track before summer gets out of control, including (1) awareness, (2) clean up, (3) building a simple plan, and then (4) execute and adjust as needed. This doesn't happen without a mindset shift, so celebrate those small victories and, before you know it, you'll have a summer bod AND a summer budget !! Let us know if you enjoy this episode and, if so, please share it with your friends! Or, you can support the show by visiting our Patreon page: https://www.patreon.com/crushingDebt   To contact George Curbelo, you can email him at GCFinancialCoach21@gmail.com or follow his Tiktok channel - https://www.tiktok.com/@curbelofinancialcoach   To contact Shawn Yesner, you can email him at Shawn@Yesnerlaw.com or visit www.YesnerLaw.com.  And although the 2026 Purple Stride walk is over, please consider a donation to Pancreatic Cancer research and education by joining Shawn's team at MY Legacy Striders: http://support.pancan.org/goto/MyLegacy2026 

What do you do when the only treatment offered isn't working? Chris Joseph, author of Life is a Ride, discusses his remarkable recovery from inoperable stage III pancreatic cancer. After traditional chemotherapy failed and his tumor continued to grow, Chris made the pivotal decision to fire his oncologist and take full command of his health "terrain."Chris shares the multi-faceted approach that led to his survival nearly a decade after his diagnosis. We dive deep into the metabolic approach to cancer, the power of intuition and why healing is never a passive process.Key Information and Time Stamps01:34 Chris recounts his "jarring" diagnosis of stage III inoperable pancreatic cancer. A critical discussion follows on how a doctor's suggestion to "go home and pray" can inadvertently rob a patient of hope07:24 The pivotal moment when Chris quit chemotherapy after his tumor continued to grow. The transition from a passive patient to an active participant and the profound peace that comes with taking responsibility for one's own healing path.12:18 Chris details his three-week intensive in Germany, highlighting integrative medicine, non-Western treatments including Vitamin C infusions, B17, ozone therapy, hyperthermia and dendritic stem cell therapy, to rebuild his immune system ravaged by chemo.16:19 A deep dive into why 90% of cancers are not hereditary. Chris and Sarah discuss environmental toxins, lifestyle choices and chronic stress as controllable factors that offer an opportunity for radical life changes.27:28 Chris shares his daily health stack: using a portable infrared sauna for 90 minutes, adopting a low-carb/keto-leaning diet and the simple but powerful mental filter of asking, "Is this food going to help me or hurt me?"32:49 A fascinating look at the nervous system's role in recovery. Sarah and Chris discuss why they both ditched the Television and how toxic news cycles agitate the body, preventing the relaxation response necessary for deep healing.40:11 Chris provides his top three tips: take charge, trust your intuition and embrace the work. He emphasizes that while healing requires immense effort, the result is a quality of life far superior to his pre-cancer years.Chris' Bio Chris Joseph is a certified Terrain Advocate in the Metabolic Approach to Cancer and a certified Radical Remission Coach. Diagnosed in 2016 with stage 3 inoperable pancreatic cancer, Chris chose to expand beyond conventional protocols and focus on transforming his internal terrain—metabolic, emotional, environmental, and spiritual. Nearly a decade later, he continues to thrive.Through one-on-one coaching, workshops, online communities, and retreats, Chris helps individuals and families take control of their health with clarity and confidence. His approach emphasizes informed choice, personal responsibility, and the understanding that healing is not passive—it requires participation.He is the author of Life is a Ride: My Unconventional Journey of Cancer Recovery.Connect with Chris https://terrainnavigators.com/https://www.facebook.com/chrisjosephInSantaMonicahttps://www.facebook.com/share/g/17GkZCy4ug/https://www.facebook.com/search/top?q=terrain%20navigatorsWho am I?Sarah Dawkins is a passionate Holistic Health and Healing Coach, international speaker and author of Heal Yourself. She's also a multi-award-winning entrepreneur and the award-winning host of the uplifting podcast Mind Body Medicine for Self Healers with Sarah Dawkins.With over 20 years' experience as a Registered Nurse, Sarah combines her deep understanding of conventional medicine with her own powerful self-healing journey to create a truly integrative approach. Having overcome multiple chronic health challenges herself, she now supports others in uncovering and addressing the root causes of their symptoms, helping them restore balance, reclaim their energy and create lasting, vibrant wellness.www.sarahdawkins.com

Joining the Project Purple Podcast from Indiana, pancreatic cancer survivor Beth Benedix has a deeply reflective and powerful conversation with host Dino Verrelli. A professor emerita of world literature, religious studies, and community engagement at DePauw University, Beth is also the founder of a nonprofit organization dedicated to bringing joy and creativity back into classrooms: an effort that reflects her lifelong passion for education and human connection. Diagnosed with pancreatic cancer in June 2020, Beth recounts her sudden diagnosis in the emergency room after experiencing severe back pain. What followed was an intense journey that included complications from testing, weeks in the hospital with pancreatitis, chemotherapy, and the Whipple procedure. Despite being declared in remission, Beth shares the emotional and physical toll of a recent recurrence, including the frustration of not being heard by medical professionals when new symptoms arose years later. Beth speaks candidly about advocating for herself within a healthcare system that can often feel dismissive, drawing parallels to the education system and the broader challenge of creating spaces where people truly feel seen and heard. Beyond her medical journey, she also reflects on identity, creativity, and the process of making meaning in the face of illness—through music, relationships, and the ways she stays grounded in connection. Rejecting the traditional “fight” narrative often associated with cancer, Beth advocates instead for individuality in how people navigate their diagnoses. Grounded in an existentialist perspective and inspired by Friedrich Nietzsche's idea to “become who you are,” Beth describes pancreatic cancer not only as a hardship, but as a vehicle for deeper self-understanding, connection, and even moments of unexpected beauty. From confronting fear and uncertainty to embracing joy, humor, and intentional relationships, Beth's story offers a profound meditation on what it means to live fully in the face of the unknown. Beth welcomes connection via email at bbenedix@depauw.edu. Subscribe to the Project Purple Podcast for more stories from the pancreatic cancer community. To learn more or donate to Project Purple's mission of a world without pancreatic cancer, visit projectpurple.org.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UEH865. CME/AAPA/IPCE credit will be available until April 21, 2027.Redefining Precision Oncology in Pancreatic Cancer: Translating Emerging KRAS-Targeted Strategies into Effective Clinical Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Revolution Medicines.Disclosure information is available at the beginning of the video presentation.

Filippo Pietrantonio from the National Cancer Institute of Milan joins the podcast to discuss the latest developments in RAS targeting in GI cancers, focusing on the exciting data with daraxonrasib in pancreatic cancer ahead of the ASCO 2026 plenary phase 3 data. We discuss the RAS pathway, prior unsuccessful targeting efforts and nuances on response and resistance.

Broadcast from KSQD, Santa Cruz on 5-07-2026: Dr. Dawn debunks the 1971 "220 minus age" maximum heart rate formula, noting a 2025 study found individual predictions were off by up to 20 beats per minute. She recommends the Tanaka equation (208 minus age) times 0.7, but emphasizes tracking improvement trends rather than absolute numbers. ConsumerLab testing found Safe Catch Wild Elite Pure Tuna and Wild Ahi Yellowfin Tuna had no detectable mercury, prompting Dr. Dawn to reconsider eating tuna after years of avoidance due to concerns about mercury bioaccumulation and its effects on nerve microtubules. A meta-analysis of 115 studies involving 55,000 men found limiting ejaculation before IVF leads to increased sperm DNA damage and poorer motility. Clinical trials showed 46% IVF pregnancy rates with less than 48 hours abstinence versus 36% with longer periods. A personalized mRNA vaccine for pancreatic cancer showed striking results: of 16 patients whose tumors were surgically removed, half produced killer T-cells targeting cancer, and seven of those eight remain alive six years later. Pfizer and Valneva's Lyme disease vaccine reduced infection by over 70% in a trial of 9,400 people ages five and up. Nearly half a million Americans contract Lyme annually, and chronic infection can cause nervous system damage and chronic fatigue. Dr. Dawn explores the gray-market peptide ecosystem, where compounds are sold as "research chemicals" with wink-and-nod marketing. A 2018 Belgian study found purity levels ranging from 5% to 99.9%, with some samples containing arsenic, lead, or industrial contaminants. A study of 450 people found that blocking smartphone internet access for two weeks improved sustained attention equivalent to reversing 10 years of age-related cognitive decline, with depression symptom improvements comparable to cognitive behavioral therapy. A multi-country study of 241 unresponsive patients found that 25% showed brain activity indicating consciousness when asked to imagine playing tennis during advanced brain scans. Scientists call this cognitive motor dissociation, and by some estimates tens of thousands of Americans may be misdiagnosed. Chinese researchers grew functional adrenal cortex organoids that responded to pituitary hormones and produced cortisol when transplanted into mice. They also introduced genetic mutations to create organoid models of Cushing's syndrome for drug testing. A Science paper identified the neural pathway connecting psychological stress to eczema flare-ups: sympathetic neurons from the stellate ganglion recruit eosinophils to the skin. Researchers traced the pathway using pseudo-rabies virus injected into skin. Mouse studies showed prenatal stress causes elevated corticosterone in amniotic fluid, which activates fetal mast cells derived from the yolk sac. Offspring develop eczema-like lesions in areas receiving mechanical stimulation, but symptoms resolve around 24 weeks when bone marrow-derived mast cells replace the activated ones. Callers ask about CBN side effects. Dr. Dawn explains cannabinoids prolong anandamide's calming effects by slowing its breakdown, and considers 30-45mg over a night reasonable, but cautions against escalating doses given limited research.

Don't skip homocysteine when testing for dementia risk factors; Treating osteoporosis; New hope against pancreatic cancer; Eating right for Parkinson's Disease; Olive oil helps stave off dementia—but only the right kind; A lifestyle hack that can cut Alzheimer's risk by 38%; How to reduce high calprotectin on a stool test.

This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2nd-line setting of metastatic pancreatic cancer compared to investigator's choice chemotherapy. Hopefully, we will get the abstract soon and publication shortly thereafter. A personalized mRNA vaccine for early-stage pancreatic cancer has some encouraging results (for those patients who mounted a sizable immune response to the vaccine). Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Episode 828: Neal and Toby discuss the ending of the Tim Cook era as Apple names their next CEO, John Ternus. Next, a breakthrough out of the science world where an mRNA vaccine given to patients with pancreatic cancer is showing lasting results after six years. Then, Bezos' Blue Origin mistakenly puts a customer's satellite in the wrong orbit in its third launch. Meanwhile, notable CEOs are achieving rockstar-like fandom among their ardent fans, even going as far buying shirts with their faces on them. Wow. Finally, FBI Director Kash Patel is suing The Atlantic.  Learn more at https://www.schwab.com/oninvesting Subscribe to Morning Brew Daily for more of the news you need to start your day. Share the show with a friend, and leave us a review on your favorite podcast app. Listen to Morning Brew Daily Here:⁠ ⁠⁠https://www.swap.fm/l/mbd-note⁠⁠⁠  Watch Morning Brew Daily Here:⁠ ⁠⁠https://www.youtube.com/@MorningBrewDailyShow⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Headlines:  – Welcome To Mo News (02:00) – Iran Ceasefire Countdown As Latest Pakistan Talks Look Iffy (07:10) – Energy Secretary Says Gas Prices May Stay Above $3 A Gallon Until 2027 (14:00) – A Look At The Democrat-Israel Divorce (15:00) – Apple Names John Ternus CEO, Replacing Tim Cook, Who Becomes Chairman (26:50) – Trump Labor Secretary Resigns Amid Scandal (30:00) – FBI Director Sues The Atlantic For $250 Million Over Story On Alleged Excessive Drinking (33:00) – As Measles Takes Toll on Kids, Anti-Vaxxers Have Change of Heart (38:10) – Pancreatic Cancer mRNA Vaccine Shows Lasting Results In Early Trial (41:00) – Back To Back Boston Marathon Winners (43:00) – Humanoid Robot Wins Half-Marathon and Smashes Humans' Record (44:10) – On This Day In History (47:10) Thanks To Our Sponsors:  – ⁠Boll & Branch⁠ – 15% off first order, plus free shipping | Code: MONEWS –⁠ Industrious⁠ - Coworking office. 50% off day pass | Code: MONEWS50 – Incogni - 60% off an annual plan| Code: MONEWS – Monarch - 50% off your first year | Code: MONEWS – Factor - 50% off your first box | Code: monews50off – ShipStation - Try for free for 60 days | Code: MONEWS – Shopify – $1 per-month trial | Code: MONEWS – LMNT | Free Sample Pack with any LMNT drink mix or 12oz cans purchase – Aura Frames | $25 dollars off the Carver Mat frame | Code: MONEWS

Headlines:  – Welcome To Mo News + Coachella  (02:00) – U.S. Begins Blockade Of Iran's Ports (07:20) – Main Sticking Points In Talks Between U.S. And Iran (14:00) – The President vs. The Pope (18:45) – Trump Explains AI Jesus Post (22:50) – Democratic Rep. Eric Swalwell Resigns From U.S. House After Sexual Assault Allegations (26:50) – Republican Rep. Tony Gonzales Also Leaving Seat After Allegations (28:00) – It's A Slow Start To The Spring Home-Buying Season (31:00) – Did Millennials or Boomers Have It Harder? We Went Searching for the Answer (32:10) – Potential Pancreatic Cancer Breakthrough: Drug Succeeds In Late-Stage Trial (35:15) – On This Day In History (37:00) Thanks To Our Sponsors:  – ⁠Boll & Branch⁠ – 15% off first order, plus free shipping | Code: MONEWS –⁠ Industrious⁠ - Coworking office. 50% off day pass | Code: MONEWS50 – Incogni - 60% off an annual plan| Code: MONEWS – Monarch - 50% off your first year | Code: MONEWS – Factor - 50% off your first box | Code: monews50off – ShipStation - Try for free for 60 days | Code: MONEWS – Shopify – $1 per-month trial | Code: MONEWS – LMNT | Free Sample Pack with any LMNT drink mix or 12oz cans purchase